Plain-English translation of NCT07061379 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether asking patients with advanced lung cancer to regularly share information about how they're feeling — including physical symptoms, mood, sleep, and overall well-being — can help doctors make better treatment decisions. Researchers will collect this patient feedback from people receiving combination chemotherapy and immunotherapy drugs like Pembrolizumab, Cemiplimab, Nivolumab, and Ipilimumab as their first treatment for lung cancer. The goal is to understand whether this patient-centered information improves both how patients feel during treatment and how well the treatment works.
Doctors currently have many different drug combinations to treat advanced lung cancer, but it's not always clear which one is best for each person. Traditional measures like survival rates don't tell the whole story — this trial exists to see whether regularly asking patients about their quality of life, emotions, sleep, and side effects can help doctors personalize treatment choices and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive one of two combination treatment regimens (your doctor will decide which based on standard care guidelines), and you'll visit the clinic regularly for your medications and check-ups over approximately 2 years or until your disease progresses. Throughout your treatment, you'll complete brief questionnaires — several times — about your physical symptoms, mood, sleep quality, and overall well-being using standardized forms. The study team will use your feedback alongside traditional medical information to see whether this patient input helps guide treatment decisions and improves your care.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Italy